Incyte Q3 GAAP net income $181.7M vs loss, revenue $812.9M (+31%); multiple approvals

INCYTE CORP

2021-Q3 EPS reported $1.73 revenue$2,123,414,000

Total product & royalty revenues $777.987M, +25% YoY; Jakafi $547.373M (+12%).
GAAP net income $181.739M ($0.82 diluted EPS) vs net loss $15.203M in Q3 2020.
Non-GAAP net income $261.824M ($1.18 diluted EPS) vs $50.059M.
FDA approved Opzelura for atopic dermatitis, Jakafi for chronic GVHD; Minjuvi OK'd in EU.
Reaffirmed FY2021 guidance: Jakafi net product rev $2,125-$2,170M; R&D $1,350-$1,390M GAAP.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.